Mirum Pharmaceuticals, Inc. $MIRM Shares Acquired by Next Century Growth Investors LLC

Next Century Growth Investors LLC boosted its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 2.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 368,035 shares of the company’s stock after purchasing an additional 7,101 shares during the quarter. Mirum Pharmaceuticals comprises approximately 2.0% of Next Century Growth Investors LLC’s investment portfolio, making the stock its 9th largest holding. Next Century Growth Investors LLC owned about 0.72% of Mirum Pharmaceuticals worth $29,071,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of MIRM. State Street Corp grew its position in Mirum Pharmaceuticals by 59.2% in the 4th quarter. State Street Corp now owns 2,143,992 shares of the company’s stock valued at $169,354,000 after purchasing an additional 797,088 shares during the period. Wellington Management Group LLP grew its position in Mirum Pharmaceuticals by 566.8% in the 3rd quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock valued at $57,965,000 after purchasing an additional 672,118 shares during the period. Arrowstreet Capital Limited Partnership grew its position in Mirum Pharmaceuticals by 709.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 612,318 shares of the company’s stock valued at $44,889,000 after purchasing an additional 536,674 shares during the period. Voloridge Investment Management LLC grew its position in Mirum Pharmaceuticals by 2,116.6% in the 3rd quarter. Voloridge Investment Management LLC now owns 389,574 shares of the company’s stock valued at $28,560,000 after purchasing an additional 371,999 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new stake in Mirum Pharmaceuticals in the 3rd quarter valued at $23,250,000.

Mirum Pharmaceuticals Trading Down 0.2%

NASDAQ:MIRM opened at $99.35 on Friday. The company has a debt-to-equity ratio of 1.28, a quick ratio of 1.99 and a current ratio of 2.09. The firm has a market cap of $6.06 billion, a price-to-earnings ratio of -7.30 and a beta of 0.50. Mirum Pharmaceuticals, Inc. has a 52 week low of $47.89 and a 52 week high of $114.99. The firm has a 50-day moving average price of $97.89 and a two-hundred day moving average price of $91.13.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($13.43) EPS for the quarter, missing the consensus estimate of ($0.75) by ($12.68). The firm had revenue of $159.88 million during the quarter, compared to analysts’ expectations of $148.21 million. Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The company’s quarterly revenue was up 43.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.30) EPS. On average, equities analysts expect that Mirum Pharmaceuticals, Inc. will post -2.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on MIRM shares. Leerink Partners reduced their price target on shares of Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating for the company in a research report on Thursday, February 26th. Stifel Nicolaus set a $136.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Wall Street Zen downgraded shares of Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Wolfe Research started coverage on shares of Mirum Pharmaceuticals in a research report on Tuesday, May 19th. They issued an “outperform” rating and a $145.00 price target for the company. Finally, TD Cowen lifted their price target on shares of Mirum Pharmaceuticals from $125.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $138.36.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, insider Joanne Quan sold 7,287 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $91.98, for a total value of $670,258.26. Following the completion of the sale, the insider owned 18,864 shares in the company, valued at approximately $1,735,110.72. This trade represents a 27.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Christopher Peetz sold 30,000 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $95.84, for a total transaction of $2,875,200.00. Following the completion of the sale, the chief executive officer owned 194,309 shares of the company’s stock, valued at approximately $18,622,574.56. This trade represents a 13.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 111,806 shares of company stock worth $10,408,916. Company insiders own 8.32% of the company’s stock.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.